Volver a Agenda
Session Chair(s)
Peter Richard Arlett, MD, FFPM, FRCP
Head Data Analytics and Methods Task Force
European Medicines Agency, Netherlands
Learning Objective : Describe the clinical course of multiple sclerosis; Describe the pathogenesis/epidemiology of progressive multifocal leukoencephalopathy in the context of natalizumab; Describe the patient/regulatory/company considerations around risk management of a serious adverse drug reaction.
Speaker(s)
Industry Perspective
Gary L. Bloomgren, MD
Biogen Idec Inc., United States
Vice President, Drug Safety and Risk Management
Panelist
John Seeger, DrPH, PHARMD
Harvard Medical School/Brigham & Women's Hospital, United States
Assistant Professor
Panelist
Patricia Saddier, MD, PHD
Merck Research Laboratories, United States
Executive Director, Pharmacoepidemiology
Patient Perspective
Melissa Tufeld, PHD
Clinical and Consulting Psychologist, United States
¿Tiene una cuenta?